Utility of a web-based breast cancer predictive algorithm for adjuvant chemotherapeutic decision making in a multidisciplinary oncology center

被引:13
作者
Epstein, Richard J.
Leung, Thomas W.
Mak, Joyce
Cheung, Polly S.
机构
[1] Univ Hong Kong, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Hong Kong Sanatorium & Hosp, Breast Care Ctr, Hong Kong, Hong Kong, Peoples R China
关键词
clinical decision support software; breast neoplasms; cancer chemotherapy;
D O I
10.1080/07357900600705292
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose : Adjuvant drug therapy can extend survival for breast cancer patients, but the balance between costs and benefits may be difficult to estimate. Software programs have been developed for this purpose and recently have become available online. Here, we describe our experience using a web-based program to support adjuvant decision making at a multidisciplinary breast cancer Tumor Board in a university-affiliated oncology center. Patients and Methods : One hundred two adjuvant breast cancer cases were discussed by the Tumor Board over a four-month period, with a provisional treatment plan being formulated after each discussion. Program data predicting 10-year risks and benefits were shared with board members after each provisional plan and any change in recommendation was recorded. A user survey was conducted to assess the perceived strengths and weaknesses of the program. Results : Treatment decisions were changed in 12.7 percent of cases (13/102) after consideration of data from the program. Most of these (76.9 percent) were node-negative ER-positive cases, with the most common reason for change being a lower-than-expected added survival benefit from less intensive chemotherapy regimens (ACx4 or CMF; 81.8 percent). In certain recurrent scenarios, the program was perceived to have limitations that led to retention of the original management plan despite data that might otherwise have favored different treatment. On completion of the study period, clinicians' attitudes to the program ranged from enthusiasm to caution. Conclusion : Although not replacing clinical judgement, these findings support the value of this web-based program as a decision making adjunct that can help clinicians to separate risk and benefit, compare the added value of different therapeutic interventions in a given clinical context, and present more balanced information about treatment options to patients.
引用
收藏
页码:367 / 373
页数:7
相关论文
共 25 条
[1]  
[Anonymous], 1988, NEW ENGL J MED, V319, P1681
[2]  
Basso Umberto, 2004, Expert Rev Anticancer Ther, V4, P197, DOI 10.1586/14737140.4.2.197
[3]  
BONADONNA G, 1977, CANCER-AM CANCER SOC, V39, P2904, DOI 10.1002/1097-0142(197706)39:6<2904::AID-CNCR2820390677>3.0.CO
[4]  
2-8
[5]  
Brown LE, 2004, ST HEAL T, V107, P711
[6]   Adjuvant chemotherapy for breast cancer: How presentation of recurrence risk influences decision-making [J].
Chao, C ;
Studts, JL ;
Abell, T ;
Hadley, T ;
Roetzer, L ;
Dineen, S ;
Lorenz, D ;
YoussefAgha, A ;
McMasters, KM .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (23) :4299-4305
[7]  
Cole Bernard F, 2004, J Biopharm Stat, V14, P111, DOI 10.1081/BIP-120028509
[8]   Considerations on the quality of medical software and information services [J].
Forsström, JJ ;
Rigby, M .
INTERNATIONAL JOURNAL OF MEDICAL INFORMATICS, 1999, 56 (1-3) :169-176
[9]   Counting the costs of treatment: the reproductive and gynaecological consequences of adjuvant therapy in young women with breast cancer [J].
Friedlander, M ;
Thewes, B .
INTERNAL MEDICINE JOURNAL, 2003, 33 (08) :372-379
[10]   Health-related quality-of-life measurement in randomized clinical trials in breast cancer - Taking stock [J].
Goodwin, PJ ;
Black, JT ;
Bordeleau, LJ ;
Ganz, PA .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (04) :263-281